Fate Therapeutics (NQ: FATE )
5.270 -0.210 (-3.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Headline News about Fate Therapeutics
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
December 22, 2022
Fate Therapeutics Initiated With Hold Rating - Read Why
July 28, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
December 12, 2022
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
August 12, 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds...
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following